• The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities
• BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies
• Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, recently presented at Recent Advances in Fermentation Technology (“RAFT”) 14, a conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”), which took place in Orlando, Florida. RAFT provides a platform for academic and industrial scientists to discuss the latest developments in fermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies at the Caribe Royale Orlando on November 8, 2022 (https://ibn.fm/ziT4B).

The RAFT presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nano-sized NanoAbs (aka VHH-antibodies and nanobodies). NanoAbs are a “bio-better” category of monoclonal antibodies (“mAbs”) providing several key advantages vs. currently…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.